Search
Menu
Home
HTB
2024
July
July 2024
Contents
Editorial
i-Base printed resources: please order now while stocks last
Conference reports
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
AIDS 2024: Introduction to AIDS 2024
UNAIDS report: The urgency of now – AIDS at a crossroads.
New community call to challenge social settings that drive HIV-related stigma
HIV research to watch out for at the AIDS 2024 conference
Antiretrovirals
HIV pipeline: global overview for people in LMICs
Treatment access
CHAI six-monthly market report (July 2024)
Guidelines
South African guidelines do not include dapivirine ring: low efficacy and high price
Updated WHO guidelines for HIV PEP (July 2024)
New US screening guidelines to reduce risk of anal cancer in people living with HIV
Side effects
Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy
HTB RSS
Early access
UK guidelines on doxyPEP to prevent syphilis
17 June 2025
APBI calls for greater participant diversity in industry studies
15 June 2025
TAG challenges HIV vaccine cuts as Robert F. Kennedy fires entire CDC vaccine expert advisory panel
6 June 2025
Gates Foundation commits to providing lenacapavir as PrEP next year
3 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
APBI calls for greater participant diversity in industry studies
15 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate